NCT03603691

Brief Summary

Many patients with multiple sclerosis (MS) are treated with physiotherapy. Muscle weakness is a common symptom. It can be evaluated with a variety of muscle function tests. In MS patients, testing muscle function can be confounded by many factors, such as spasticity and ataxia, which are not considered by the existing tests and may cause biased test results. Steinlin Egli described a Modified Manual Muscle Test (MMMT) that considers spasticity and may provide a more reliable and valid muscle function test for MS patients. The investigators aim to evaluate the inter- and intra-rater reliability of the Modified Manual Muscle Test in MS and evaluate the validity of the Modified MMT according to the criteria of the 6 level British Medical Research Council (BMRC) manual muscle test and the microFET2 handhold dynamometer.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
28

participants targeted

Target at P25-P50 for not_applicable multiple-sclerosis

Timeline
Completed

Started Aug 2018

Shorter than P25 for not_applicable multiple-sclerosis

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 19, 2018

Completed
1 month until next milestone

First Posted

Study publicly available on registry

July 27, 2018

Completed
5 days until next milestone

Study Start

First participant enrolled

August 1, 2018

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 15, 2018

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 29, 2019

Completed
Last Updated

January 30, 2019

Status Verified

January 1, 2019

Enrollment Period

5 months

First QC Date

June 19, 2018

Last Update Submit

January 29, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Inter-rater reliability Modified Manual Muscle Test

    The primary endpoint is the MMMT level. The ordinal levels (2+, 3-, 3, 4-, 4, 4+ and 5) will be transformed to ranks (1-7), and the intra-class correlation coefficient (ICC) of the ranked MMMT levels will be estimated. The aim is to show that the MMMT results are at a clinically relevant - thus high - level of ICC (that is a pre-specified, clinically relevant level the ICC margin). The null hypothesis is that the lower limit of the 95% confidence interval (CI) of the ICC is smaller than or equal to the ICC margin. The alternative hypothesis is that the lower limit of the 95% CI of the ICC is larger than the ICC margin. If the lower limit of the CI is larger than the ICC margin, the MMMT will be considered a reliable tool for evaluating muscle strength in MS patients.

    Baseline

Secondary Outcomes (3)

  • Intra-rater reliability Modified Manual Muscle Test

    Baseline- Baseline plus 4 hours

  • Validity of the Modified Manual Muscle Test

    Baseline- Baseline plus 4 hours

  • Modified Tardieu Scale level

    Baseline- Baseline plus 4 hours

Other Outcomes (1)

  • Bias testing Fatigue

    Baseline- Baseline plus 4 hours

Study Arms (3)

Modified Manual Muscle Test

ACTIVE COMPARATOR

The MMMT will be tested in a test-retest design

Diagnostic Test: Modified Manual Muscle TestDiagnostic Test: BMRC manual muscle testDiagnostic Test: MicroFET2 handhold dynamometerDiagnostic Test: Modified Tardieu ScaleDiagnostic Test: Fatigue Scale for Motor and Cognitive FunctionsDiagnostic Test: numeric rating scale Fatigue

Neurostatus BMRC

ACTIVE COMPARATOR

The Neurostatus BMRC measures Strength and will be used in a test-retest design

Diagnostic Test: Modified Manual Muscle TestDiagnostic Test: BMRC manual muscle testDiagnostic Test: MicroFET2 handhold dynamometerDiagnostic Test: Modified Tardieu ScaleDiagnostic Test: Fatigue Scale for Motor and Cognitive FunctionsDiagnostic Test: numeric rating scale Fatigue

MicroFET2

ACTIVE COMPARATOR

The MicroFET2 is a hand held dynamometer to measure strength

Diagnostic Test: Modified Manual Muscle TestDiagnostic Test: BMRC manual muscle testDiagnostic Test: MicroFET2 handhold dynamometerDiagnostic Test: Modified Tardieu ScaleDiagnostic Test: Fatigue Scale for Motor and Cognitive FunctionsDiagnostic Test: numeric rating scale Fatigue

Interventions

Manual Muscle Testing Grading System from 0=No visible or palpable contraction to 5= full range of movement against gravity, maximal resistance

MicroFET2Modified Manual Muscle TestNeurostatus BMRC

muscle scale grades muscle power on a scale of 0 to 5 in relation to the maximum expected for that muscle

MicroFET2Modified Manual Muscle TestNeurostatus BMRC

MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various muscle groups

MicroFET2Modified Manual Muscle TestNeurostatus BMRC
Modified Tardieu ScaleDIAGNOSTIC_TEST

Modified Tardieu Scale is to measure if there is spasticity present in a person's muscle and its response to movement

MicroFET2Modified Manual Muscle TestNeurostatus BMRC

Measures cognitive and motor fatigue for people with MS

MicroFET2Modified Manual Muscle TestNeurostatus BMRC

visual analog scale that uses a scalar numbering system to objectify a patient's fatigue (0 = no fatigue; 10 = most extreme fatigue)

MicroFET2Modified Manual Muscle TestNeurostatus BMRC

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • diagnosed with MS according to the McDonald criteria
  • EDSS between 0 and 6.5
  • older than 18 years of age.

You may not qualify if:

  • An acute episode of MS within 3 months prior to the testing,
  • grave cognitive changes
  • distinct fatigue
  • a history of current back, neck or elbow pain

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Felix Platter Hospital

Basel, 4055, Switzerland

Location

MeSH Terms

Conditions

Multiple Sclerosis

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNervous System DiseasesDemyelinating DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

  • Nico van der Maas

    Institute for Physiotherapy Research, Biel, Switzerland

    PRINCIPAL INVESTIGATOR
  • Marcus Dsouza, Dr. med.

    University Hospital Basle, Basle, Switzerland

    PRINCIPAL INVESTIGATOR
  • Regula Steinlin Egli

    Specialized Group Physiotherapy in MS, Binningen, Switzerland

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
the outcome assessors will be blinded for the results of other assessors.
Purpose
DIAGNOSTIC
Intervention Model
CROSSOVER
Model Details: Prospective, cross-sectional and test-retest
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principle Investigator

Study Record Dates

First Submitted

June 19, 2018

First Posted

July 27, 2018

Study Start

August 1, 2018

Primary Completion

December 15, 2018

Study Completion

January 29, 2019

Last Updated

January 30, 2019

Record last verified: 2019-01

Locations